C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab is a first-generation C5 inhibitor and the first disease-specific treatment to be approved for patients with PNH, offering terminal complement inhibition through a biweekly intravenous dosing regimen [11, 12].